NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer

Impact · against what's priced in

The article provides no new catalysts for RVMD, MRNA, or MRK, as it merely summarizes clinical milestones and FDA approvals already factored into their valuations. NeOnc (NTHI) remains a speculative follow-on based on its Phase 2a survival data, but no new material developments are reported beyond the existing catalyst for FDA discussions.

MRK+0.00

Already priced in

The price assumes

the full upside of the mRNA cancer vaccine (Intismeran) with Keytruda